X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (168) 168
index medicus (128) 128
male (124) 124
female (121) 121
middle aged (120) 120
aged (104) 104
adult (103) 103
life sciences (87) 87
cancer (83) 83
hematology (83) 83
oncology (82) 82
rituximab (57) 57
lymphomas (56) 56
antineoplastic combined chemotherapy protocols - therapeutic use (54) 54
aged, 80 and over (51) 51
chemotherapy (51) 51
treatment outcome (51) 51
lymphoma (50) 50
prognosis (50) 50
non-hodgkins-lymphoma (49) 49
[ sdv.can ] life sciences [q-bio]/cancer (39) 39
[sdv.can]life sciences [q-bio]/cancer (33) 33
b-cell lymphoma (31) 31
elderly-patients (31) 31
lymphoma, large b-cell, diffuse - drug therapy (31) 31
survival (30) 30
abridged index medicus (28) 28
adolescent (28) 28
hemic and lymphatic diseases (27) 27
disease-free survival (26) 26
retrospective studies (26) 26
young adult (25) 25
therapy (24) 24
survival analysis (23) 23
antineoplastic combined chemotherapy protocols - adverse effects (22) 22
cyclophosphamide (22) 22
cyclophosphamide - administration & dosage (21) 21
follow-up studies (21) 21
risk factors (21) 21
expression (20) 20
kaplan-meier estimate (20) 20
antineoplastic agents - therapeutic use (19) 19
care and treatment (19) 19
doxorubicin - administration & dosage (19) 19
prospective studies (19) 19
cyclophosphamide - therapeutic use (18) 18
lymphoma, large b-cell, diffuse - mortality (18) 18
neoplasm staging (18) 18
trial (18) 18
clinical trials (17) 17
doxorubicin (17) 17
immune system diseases (17) 17
vincristine - administration & dosage (17) 17
doxorubicin - therapeutic use (16) 16
fluorodeoxyglucose f18 (16) 16
lymphoma, large b-cell, diffuse - pathology (16) 16
pathology (16) 16
prednisone - therapeutic use (16) 16
antibodies, monoclonal, murine-derived (15) 15
antibodies, monoclonal, murine-derived - therapeutic use (15) 15
antineoplastic combined chemotherapy protocols - administration & dosage (15) 15
follicular lymphoma (15) 15
lymphoma, follicular - drug therapy (15) 15
lymphoma, large b-cell, diffuse - diagnosis (15) 15
prednisone - administration & dosage (15) 15
antibodies, monoclonal, murine-derived - administration & dosage (14) 14
vincristine (14) 14
[ sdv ] life sciences [q-bio] (13) 13
[sdv]life sciences [q-bio] (13) 13
analysis (13) 13
diagnosis (13) 13
drug administration schedule (13) 13
france (13) 13
malignant-lymphoma (13) 13
medical research (13) 13
patients (13) 13
pet (13) 13
positron-emission tomography - methods (13) 13
positron-emission-tomography (13) 13
prednisone (13) 13
risk (13) 13
time factors (13) 13
radiology, nuclear medicine & medical imaging (12) 12
recurrence (12) 12
survival rate (12) 12
vincristine - therapeutic use (12) 12
aggressive lymphoma (11) 11
antibodies, monoclonal - administration & dosage (11) 11
antineoplastic agents - administration & dosage (11) 11
classification (11) 11
diffuse large b-cell lymphoma (11) 11
follow-up (11) 11
human health and pathology (11) 11
immunochemotherapy (11) 11
lymphoma, follicular - pathology (11) 11
lymphoma, large b-cell, diffuse - genetics (11) 11
multivariate analysis (11) 11
mutation (11) 11
predictive value of tests (11) 11
r-chop (11) 11
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2011, Volume 377, Issue 9759, pp. 42 - 51
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 388, Issue 10044, pp. 565 - 575
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9806, pp. 1858 - 1867
Summary Background The outcome of diffuse large B-cell lymphoma has been substantially improved by the addition of the anti-CD20 monoclonal antibody rituximab... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | MULTICENTER | RESPONSE CRITERIA | AGGRESSIVE LYMPHOMAS | POOR-PROGNOSIS | NON-HODGKINS-LYMPHOMA | REGIMEN | YOUNG-PATIENTS | ELDERLY-PATIENTS | DES-LYMPHOMES | TRANSPLANTATION | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Dose-Response Relationship, Drug | Young Adult | Vindesine - adverse effects | Adult | Female | Prednisolone | Doxorubicin - administration & dosage | Severity of Illness Index | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Risk Assessment | Rituximab | Treatment Outcome | Bleomycin - administration & dosage | Bleomycin - adverse effects | Vincristine | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - diagnosis | Maximum Tolerated Dose | Adolescent | Survival Analysis | Vindesine - administration & dosage | Doxorubicin - adverse effects | Chemotherapy | Physiological aspects | Lymphomas | B cells | Drug therapy | Methods | Cancer | Dehydrogenases | Toxicity | Population studies | Doxorubicin | Hepatitis | Randomization | Bleomycin | Motivation | Drug dosages | Neutropenia | Cell survival | Hematology | Prednisone | Survival | Patients | Lymphoma | Cyclophosphamide | Lymphocytes B | Monoclonal antibodies | CD20 antigen | Tumors | B-cell lymphoma | Clinical trials | Public speaking | Grants | Clinical medicine | Side effects | lymphoma | survival | International standardization | chemotherapy
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 6, pp. 525 - 533
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 5, pp. 460 - 468
Summary Background Diffuse large B-cell lymphoma is a common cancer in elderly patients. Although treatment has been standardised in younger patients, no... 
Hematology, Oncology and Palliative Medicine | MAINTENANCE RITUXIMAB | COLONY-STIMULATING FACTOR | PROGNOSTIC-FACTORS | RESPONSE CRITERIA | ONCOLOGY | AGGRESSIVE LYMPHOMAS | MALIGNANT-LYMPHOMAS | NON-HODGKINS-LYMPHOMA | COMPREHENSIVE GERIATRIC ASSESSMENT | DETUDE-DES-LYMPHOMES | CHOP CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Prospective Studies | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Aged, 80 and over | Vincristine - administration & dosage | Female | France | Odds Ratio | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Lymphoma, Large B-Cell, Diffuse - pathology | Risk Assessment | Risk Factors | Rituximab | Treatment Outcome | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Analysis of Variance | Belgium | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Vincristine - adverse effects | Doxorubicin - adverse effects | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Anthracyclines | Cyclophosphamide | Chemotherapy | Corticosteroids | Oncology, Experimental | Aged patients | Product development | Prednisone | Lymphomas | Research | Cancer | Toxicity | Albumin | Clinical trials | Multivariate analysis | Doxorubicin | Survival | Vincristine | Side effects | Motivation | Age | rituximab | B-cell lymphoma | Geriatrics | Neutropenia
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2016, Volume 34, Issue 30, pp. 3618 - 3626
Purpose Identifying patients at high risk of progression and early death among those with high-tumor-burden follicular lymphoma (FL) is unsatisfactory with... 
FDG-PET | SURVIVAL | IMMUNOCHEMOTHERAPY | POSITRON-EMISSION-TOMOGRAPHY | ONCOLOGY | CYCLOPHOSPHAMIDE | RESPONSE ASSESSMENT | VINCRISTINE | NON-HODGKIN-LYMPHOMA | R-CVP | PROGNOSTIC VALUE | Life Sciences | Cancer
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2017, Volume 377, Issue 13, pp. 1250 - 1260
Journal Article
Journal Article